title: [Successful Administration of Regorafenib to a Metastatic Colon Cancer Patient with Impaired Performance Status by Reducing the Initial Dose].
abstract: A 59-year-old woman had recurrences in the spleen and lung 10 years after radical excision of cecal cancer. After 27 months of treatment with 5-fluorouracil/Leucovorin, oxaliplatin, irinotecan, bevacizumab, and anti-EGFR antibodies, multiple bone metastases and a left adrenal metastasis developed, and the patient's performance status (PS) deteriorated to grade 3. Regorafenib was administered at 80 mg/day. The pain and appetite improved within 2 courses, and her PS improved from grade 3 to 2. Regorafenib was increased to 120 mg/day for the 2nd course, and the patient was treated for 5 months without severe adverse effects. Regorafenib is considered to be a salvage-line treatment only for patients in relatively good condition, because full-dose regorafenib treatment often leads to severe adverse effects. Dose escalation of regorafenib from the low initial dose of 80 mg/day may be a safe and effective way of providing an opportunity of this chemotherapy to patients with impaired PS.
authors.affiliation: Dept. of Surgery, Kyoto Katsura Hospital.
authors.forename: Ryuta
authors.initials: R
authors.lastname: Nishitai
authors.forename: Dai
authors.initials: D
authors.lastname: Manaka
authors.forename: Ryo
authors.initials: R
authors.lastname: Kudo
authors.forename: Eisei
authors.initials: E
authors.lastname: Mitsuoka
authors.forename: Shumpei
authors.initials: S
authors.lastname: Kanai
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kanto
authors.forename: Kenji
authors.initials: K
authors.lastname: Yoshino
authors.forename: Shin-ya
authors.initials: SY
authors.lastname: Hamasu
authors.forename: Sayuri
authors.initials: S
authors.lastname: Konishi
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Yamashiro
mesh_terms: D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D010671:Phenylurea Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013160:Splenic Neoplasms / Q000188:drug therapy* / Q000556:secondary; D014057:Tomography, X-Ray Computed
chemical_list: D010671:Phenylurea Compounds; D011725:Pyridines; C559147:regorafenib